Who owns Akebia Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of AKBA from SEC Form 13F filings across 170 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 170 institutions disclosed 107.9M shares of Akebia Therapeutics, Inc. worth $123.2M — about 40% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
170
13F holders
$123.2M
value, 2026 filers
40%
of shares outstanding (107.9M sh)
38
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of AKBA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 20.0M | $22.8M | 0.0% | 7.4% | +6.9% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 11.3M | $12.9M | 0.0% | 4.2% | +1.4% |
| 3 | AQR CAPITAL MANAGEMENT LLC | 9.2M | $10.4M | 0.0% | 3.4% | +410.5% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 6.7M | $7.7M | 0.0% | 2.5% | +4.3% |
| 5 | STATE STREET CORP | 5.4M | $6.1M | 0.0% | 2% | -53.6% |
| 6 | JACOBS LEVY EQUITY MANAGEMENT, INC | 4.3M | $4.9M | 0.0% | 1.6% | +894.5% |
| 7 | ACADIAN ASSET MANAGEMENT LLC | 4.0M | $4.6M | 0.0% | 1.5% | +190.8% |
| 8 | GOLDMAN SACHS GROUP INC | 3.7M | $4.2M | 0.0% | 1.4% | +2.4% |
| 9 | MILLENNIUM MANAGEMENT LLC | 3.2M | $3.6M | 0.0% | 1.2% | +34.0% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.5M | $2.9M | 0.0% | 0.9% | +14.4% |
| 11 | TWO SIGMA INVESTMENTS, LP | 2.4M | $2.8M | 0.0% | 0.9% | +87.8% |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.3M | $2.6M | 0.0% | 0.9% | +14.1% |
| 13 | NORTHERN TRUST CORP | 2.2M | $2.5M | 0.0% | 0.8% | +11.0% |
| 14 | Nantahala Capital Management, LLC | 2.0M | $2.3M | 0.1% | 0.7% | 0.0% |
| 15 | VANGUARD FIDUCIARY TRUST CO | 1.9M | $2.2M | 0.0% | 0.7% | +7.3% |
| 16 | FMR LLC | 1.9M | $2.1M | 0.0% | 0.7% | +40.1% |
| 17 | Qube Research & Technologies Ltd | 1.8M | $2.0M | 0.0% | 0.7% | -25.7% |
| 18 | CITADEL ADVISORS LLC | 1.7M | $2.0M | 0.0% | 0.6% | +23.6% |
| 19 | UBS Group AG | 1.4M | $1.6M | 0.0% | 0.5% | +78.7% |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 1.2M | $1.4M | 0.0% | 0.5% | -33.2% |
| 21 | CITIGROUP INC | 1.1M | $1.3M | 0.0% | 0.4% | -60.6% |
| 22 | Hennion & Walsh Asset Management, Inc. | 839,729 | $957,291 | 0.0% | 0.3% | +32.6% |
| 23 | MORGAN STANLEY | 701,540 | $799,756 | 0.0% | 0.3% | +20.7% |
| 24 | Invesco Ltd. | 694,928 | $792,218 | 0.0% | 0.3% | -3.5% |
| 25 | MANGROVE PARTNERS IM, LLC | 666,954 | $760,328 | 0.0% | 0.2% | +77.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.